Abstract
Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Current Stem Cell Research & Therapy
Title:Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Volume: 13 Issue: 5
Author(s): Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*
Affiliation:
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Abstract: Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Export Options
About this article
Cite this article as:
Li Feng , Zhang Tengfei , Cao Ling and Zhang Yi *, Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180420110239
DOI https://dx.doi.org/10.2174/1574888X13666180420110239 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Complementary Medicine Amongst Patients on Antiretroviral Drugs in an HIV Treatment Centre in Lagos, Nigeria
Current Drug Safety Subject Index To Volume 13
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Peptide Nucleic Acids with a Structurally Biased Backbone. Updated Review and Emerging Challenges
Current Topics in Medicinal Chemistry Alcoholic Liver Disease and Hepatitis C Chronic Infection
Reviews on Recent Clinical Trials The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Selective Histone Deacetylase Inhibitors with Anticancer Activity
Current Topics in Medicinal Chemistry Tachykinins and their Receptors in Human Malignancies
Current Drug Targets HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued)